Blog | BioInformant

Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating iPS Cells

December 17, 2019 By Cade Hildreth, Founder & President Leave a Comment

Lineage Cell and AgeX get issued U.S. Patent that Precedes the first scientific publication of Shinya Yamanaka.

CARLSBAD, Calif., Dec 10, 2019 — Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) and AgeX Therapeutics, Inc. (NYSE American: AGE), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,501,723, entitled “Methods of Reprogramming Animal Somatic Cells” covering what is commonly designated “induced Pluripotent Stem (iPS) cells.” The issued claims include methods to manufacture pluripotent cells capable of becoming any cell in the body.

The patent has an early priority date, having been filed before the first scientific publication of Shinya Yamanaka, for which he won the Nobel Prize for Physiology or Medicine in 2012. [Read more…]

Adaptimmune Receives RMAT Designation for ADP-A2M4 for Synovial Sarcoma

December 5, 2019 By Cade Hildreth, Founder & President Leave a Comment

On December 3, 2019, Adaptimmune Therapeutics (Nasdaq:ADAP) announced it has been granted an Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. FDA for ADP-A2M4 in the treatment of Synovial Sarcoma. Previously, the FDA had awarded an Orphan Drug Designation (ODD) to ADP-A2M4 for the treatment of soft tissue sarcomas.

This RMAT designation represents the 38th publicly announced RMAT within the United States. [Read more…]

CAR-T Cell Therapy Attracts Vast Sums of Money

December 5, 2019 By Cade Hildreth, Founder & President Leave a Comment

What is CAR-T therapy? Chimeric antigen receptor T-cell (CAR-T) therapy is a targeted approach to treating cancer that uses a patient’s T cells, which are a type of immune system cell.

Since the first CAR-T therapy approvals in 2017 by the U.S. FDA, CAR-T deal-making has attracted vast sums of money. This article summarizes recent partnerships and deal-making with the CAR-T marketplace. [Read more…]

KATAOKA Introduces CPD-017 Cell Processor for High-Speed Biomanufacturing

November 26, 2019 By Cade Hildreth, Founder & President Leave a Comment

Unwanted cell removal and cell sorting can be easily performed at high-speed.

TORRANCE, Calif. – Kataoka-SS America, a US subsidiary of Kataoka Corporation Kyoto Japan, has launched its sales of their Cell Processor CPD-017 to the U.S. market. Kataoka`s Cell Processor uses laser technology to scan, identify, and irradiate spontaneously differentiated cells without dissociation or applied stress to the cells.

With the CPD-017, the process time of purifying induced pluripotent stem cell (iPSC) is significantly reduced and the adherent cell colonies can maintain a stress-free healthy condition. [Read more…]

CBR Announces New Pediatric Genetic Screening Test in Collaboration with Sema4

November 20, 2019 By Cade Hildreth, Founder & President Leave a Comment

Sema4 collaborated with CBR to launch ReadyGen™, a genetic screening test that analyzes a child’s DNA for 200+ conditions.

LOS ANGELES, Nov. 15, 2019 — CBR, the global leader in newborn stem cell banking, has announced a new genetic service developed over the past couple of years as part of a strategic alliance with Sema4. As a patient-centered health intelligence company and leading innovator within the genomic testing industry, Sema4 collaborated with CBR to launch ReadyGen™, a highly accurate genetic screening test that analyzes a child’s DNA for more than 200 conditions that can affect children before the age of 10. [Read more…]